The Claim
Rare pathogenic missense variants in the SRSF2 gene are associated with a significantly reduced lifespan, with carriers exhibiting a hazard ratio of 5.8 for earlier mortality compared to non-carriers, based on analysis of 393,833 individuals of European ancestry; the allele frequency distribution indicates that clonal hematopoiesis, a pre-leukemic condition, contributes to this association.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with rare harmful changes in the SRSF2 gene tend to die earlier — about 5.8 times more likely — than those without it, and this might be because of a blood condition that can lead to leukemia.
See the scientific wording
Rare pathogenic missense variants in the SRSF2 gene are associated with a dramatically reduced lifespan, with carriers having a hazard ratio of 5.8 for earlier mortality compared to non-carriers, based on analysis of 393,833 individuals of European ancestry. The variant allele frequency distribution suggests these associations are partly driven by clonal hematopoiesis, a pre-leukemic condition.
What the research says
1 studyStudy: Rare genetic associations with human lifespan in UK Biobank are enriched for oncogenic genes
The study found that people with certain rare genetic changes in the SRSF2 gene tend to live shorter lives, and this may be linked to blood conditions that can lead to cancer, which matches the main idea of the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.